600196 复星医药
2025/03 - 三个月
人民幣(K¥)
与去年同期
比较
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
营业总收入9,420,323-7.26%41,067,19641,399,54043,951,54739,011,184
减:营业总成本9,130,342-4.12%39,397,51241,284,07741,346,26437,093,266
    其中:营业成本4,920,296-3.10%21,365,57421,595,30923,169,69020,229,785
               财务费用277,183-1.08%1,110,518984,323647,403464,022
               资产减值损失(10,549)-279.24%(96,570)(219,742)(272,488)(829,873)
公允价值变动收益(281,745)1,299.12%(115,939)(427,380)(2,498,368)352,299
投资收益1,281,382281.87%2,104,6073,501,9934,377,8434,623,826
    其中:对联营企业和合营企业的投资收益385,77616.79%1,643,8392,184,8491,835,1461,789,137
营业利润1,358,77133.03%4,245,1043,307,5084,656,6566,302,568
利润总额1,347,54232.32%4,169,2823,264,5684,574,3826,042,671
减:所得税费用405,97674.84%656,841369,504626,9171,066,401
净利润941,56619.76%3,512,4402,895,0633,947,4644,976,269
减:非控股权益176,8090.18%742,554508,798216,660247,559
股东净利润764,75825.42%2,769,8872,386,2663,730,8054,728,711

市场价值指针
每股收益 (元) *0.29026.09%1.0400.8901.4301.850
每股派息 (元) *----0.3200.2700.4200.560
每股净资产 (元) *17.9403.45%17.70017.11016.68415.292
审计意见 #--标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容